NCT00077194View on ClinicalTrials.gov

FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

December 31, 2005

Conditions
Lymphoma
Interventions
DRUG

romidepsin

Trial Locations (4)

20060

Howard University Cancer Center at Howard University Hospital, Washington D.C.

21231

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

48201-1379

Barbara Ann Karmanos Cancer Institute, Detroit

53792-5256

University of Wisconsin Comprehensive Cancer Center, Madison

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00077194 - FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter